 Tumor Necrosis Factor-alpha
"Tumor Necrosis Factor-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
| Descriptor ID |
D014409
|
| MeSH Number(s) |
D12.644.276.374.500.800 D12.644.276.374.750.626 D12.644.276.972.626 D12.776.124.900 D12.776.395.930 D12.776.467.374.500.800 D12.776.467.374.750.626 D12.776.467.972.626 D23.529.374.500.800 D23.529.374.750.626 D23.529.972.626
|
| Concept/Terms |
Tumor Necrosis Factor-alpha- Tumor Necrosis Factor-alpha
- Tumor Necrosis Factor alpha
- Cachectin-Tumor Necrosis Factor
- Cachectin Tumor Necrosis Factor
- TNFalpha
- TNF-alpha
- Tumor Necrosis Factor
- Tumor Necrosis Factor Ligand Superfamily Member 2
- Cachectin
- TNF Superfamily, Member 2
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor-alpha".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor-alpha".
This graph shows the total number of publications written about "Tumor Necrosis Factor-alpha" by people in this website by year, and whether "Tumor Necrosis Factor-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 1 | 0 | 1 | | 1988 | 4 | 0 | 4 | | 1989 | 4 | 3 | 7 | | 1990 | 7 | 3 | 10 | | 1991 | 10 | 2 | 12 | | 1992 | 6 | 5 | 11 | | 1993 | 2 | 3 | 5 | | 1994 | 6 | 4 | 10 | | 1995 | 11 | 7 | 18 | | 1996 | 6 | 3 | 9 | | 1997 | 4 | 5 | 9 | | 1998 | 2 | 7 | 9 | | 1999 | 4 | 12 | 16 | | 2000 | 4 | 6 | 10 | | 2001 | 10 | 10 | 20 | | 2002 | 13 | 8 | 21 | | 2003 | 10 | 12 | 22 | | 2004 | 16 | 16 | 32 | | 2005 | 8 | 10 | 18 | | 2006 | 9 | 14 | 23 | | 2007 | 15 | 15 | 30 | | 2008 | 6 | 12 | 18 | | 2009 | 8 | 7 | 15 | | 2010 | 7 | 13 | 20 | | 2011 | 6 | 15 | 21 | | 2012 | 10 | 17 | 27 | | 2013 | 10 | 6 | 16 | | 2014 | 4 | 11 | 15 | | 2015 | 5 | 12 | 17 | | 2016 | 2 | 8 | 10 | | 2017 | 6 | 9 | 15 | | 2018 | 4 | 9 | 13 | | 2019 | 3 | 8 | 11 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Necrosis Factor-alpha" by people in Profiles.
-
Jain A, Irizarry-Caro RA, McDaniel MM, Chawla AS, Carroll KR, Overcast GR, Philip NH, Oberst A, Chervonsky AV, Katz JD, Pasare C. T cells instruct myeloid cells to produce inflammasome-independent IL-1ß and cause autoimmunity. Nat Immunol. 2020 01; 21(1):65-74.
-
Katsumata K, Ishihara J, Mansurov A, Ishihara A, Raczy MM, Yuba E, Hubbell JA. Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of anti-inflammatory antibodies. Sci Adv. 2019 11; 5(11):eaay1971.
-
Bertucci Zoccali M, Hyman NH, Skowron KB, Rubin M, Cannon LM, Hurst RD, Umanskiy K, Rubin DT, Shogan BD. Exposure to Anti-tumor Necrosis Factor Medications Increases the Incidence of Pouchitis After Restorative Proctocolectomy in Patients With Ulcerative Colitis. Dis Colon Rectum. 2019 11; 62(11):1344-1351.
-
Feld L, Glick LR, Cifu AS. Diagnosis and Management of Crohn Disease. JAMA. 2019 May 14; 321(18):1822-1823.
-
Lu TX, Cohen RD. Maneuvering Clinical Pathways for Crohn's Disease. Curr Gastroenterol Rep. 2019 Apr 23; 21(5):20.
-
Dwadasi S, Israel A, Rubin DT. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know? Gastrointest Endosc Clin N Am. 2019 Jul; 29(3):405-419.
-
Graham WV, He W, Marchiando AM, Zha J, Singh G, Li HS, Biswas A, Ong MLDM, Jiang ZH, Choi W, Zuccola H, Wang Y, Griffith J, Wu J, Rosenberg HJ, Wang Y, Snapper SB, Ostrov D, Meredith SC, Miller LW, Turner JR. Intracellular MLCK1 diversion reverses barrier loss to restore mucosal homeostasis. Nat Med. 2019 04; 25(4):690-700.
-
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 03; 114(3):384-413.
-
Paschalis EI, Taniguchi EV, Chodosh J, Pasquale LR, Colby K, Dohlman CH, Shen LQ. Blood Levels of Tumor Necrosis Factor Alpha and Its Type 2 Receptor Are Elevated in Patients with Boston Type I Keratoprosthesis. Curr Eye Res. 2019 06; 44(6):599-606.
-
Hinze CH, Foell D, Johnson AL, Spalding SJ, Gottlieb BS, Morris PW, Kimura Y, Onel K, Li SC, Grom AA, Taylor J, Brunner HI, Huggins JL, Nocton JJ, Haines KA, Edelheit BS, Shishov M, Jung LK, Williams CB, Tesher MS, Costanzo DM, Zemel LS, Dare JA, Passo MH, Ede KC, Olson JC, Cassidy EA, Griffin TA, Wagner-Weiner L, Weiss JE, Vogler LB, Rouster-Stevens KA, Beukelman T, Cron RQ, Kietz D, Schikler K, Mehta J, Ting TV, Verbsky JW, Eberhard AB, Huang B, Giannini EH, Lovell DJ. Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Arthritis Rheumatol. 2019 03; 71(3):451-459.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|